{"organizations": [], "uuid": "1ae7deb740fd2e62c1fbd6063c7b6e1293303c0a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/public/resources/images/BN-KY046_1026va_G_20151026114051.jpg", "site_section": "http://www.wsj.com/news/markets", "section_title": "Stock Market &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/can-valeant-again-be-valeant-1445880983", "country": "US", "title": "Can Valeant Again Be Valeant?", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "Can Valeant Again Be Valeant? - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-10-26T20:36:00.000+02:00", "replies_count": 0, "uuid": "1ae7deb740fd2e62c1fbd6063c7b6e1293303c0a"}, "author": "Charley Grant", "url": "http://www.wsj.com/articles/can-valeant-again-be-valeant-1445880983", "ord_in_thread": 0, "title": "Can Valeant Again Be Valeant?", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "The call wasn’t a cure-all. Valeant Pharmaceuticals International was able to stanch its share-price wound with Monday’s special conference call for investors. But value hunters should hold their fire until they get more clarity on how the issues around its specialty pharmacy business affect the Valeant business model.\nValeant gave investors some answers around its relationship with specialty pharmacy Philidor RX—it paid $100 million for the right to purchase Philidor for no additional cash outlay. The board also... ", "external_links": [], "published": "2015-10-26T20:36:00.000+02:00", "crawled": "2015-10-26T19:42:05.442+02:00", "highlightTitle": ""}